{"id":"W2025016054","doi":"10.1007/s10456-014-9420-y","title":"Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions","year":2014,"lang":"en","type":"review","venue":"Angiogenesis","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":736,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Royal Marsden NHS Foundation Trust","keywords":"Bevacizumab; Sunitinib; Medicine; Vascular endothelial growth factor; Angiogenesis; Aflibercept; Cancer research; Targeted therapy; Disease; Vascular endothelial growth factor A; Oncology; VEGF receptors; Chemotherapy; Cancer; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001024662,0.0007094706,0.001275021,0.001581346,0.0003585732,0.001304943,0.0008207525,0.001256723,0.003345768],"category_scores_gemma":[0.001063177,0.0002591881,0.0004262769,0.002089875,0.0007680722,0.002181576,0.0007410262,0.00272778,0.002106254],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008180579,"about_ca_system_score_gemma":0.001089827,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007260778,"about_ca_topic_score_gemma":0.001424157,"domain_scores_codex":[0.999723,0.00006162874,0.00003663653,0.00003991189,0.0001082737,0.00003051615],"domain_scores_gemma":[0.9994387,0.0003001332,0.00005067236,0.00001778462,0.0001403765,0.00005233625],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006245239,0.00007802433,0.0001135406,0.01042754,0.00004949337,0.00016685,0.00007453282,0.000345298,0.001944428,0.006102556,0.04032717,0.9403082],"study_design_scores_gemma":[0.00001072446,0.00006051423,0.000339709,0.002033354,0.00003970744,0.0009359141,0.00004978102,0.00008047857,0.0003028891,0.002920736,0.9932123,0.00001388786],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005864522,0.998377,0.0001226106,0.0005807394,0.0002623123,0.000002538529,0.000006882678,0.000006044605,0.0005833744],"genre_scores_gemma":[0.0004054228,0.9984659,0.0001801894,0.0002758151,0.0002403975,0.000003906911,0.00001132113,0.000001755537,0.0004153499],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003345768,"threshold_uncertainty_score":0.01119268,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02999075197384412,"score_gpt":0.3550435051925295,"score_spread":0.3250527532186854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}